Kannourakis G - Search Results

1

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.

Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P, Ahmed N. Sharma R, et al. Among authors: kannourakis g. J Exp Clin Cancer Res. 2021 Jun 7;40(1):186. doi: 10.1186/s13046-021-01961-3. J Exp Clin Cancer Res. 2021. PMID: 34099013 Free PMC article. Review.

2

Studies by radioiodination of normal adult, fetal and leukemic cell membranes.

Kannourakis G, Cauchi MN. Kannourakis G, et al. Exp Hematol. 1978 Sep;6(8):655-60. Exp Hematol. 1978. PMID: 361426

3

Osmotic fragility of leukaemic and normal lymphocytes.

Kannourakis G, Cauchi MN. Kannourakis G, et al. Pathology. 1978 Apr;10(2):131-4. doi: 10.3109/00313027809063490. Pathology. 1978. PMID: 277889

4

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Escudier B, et al. Among authors: kannourakis g. Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823696 Free PMC article. Clinical Trial.

5

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A. Davis ID, et al. Among authors: kannourakis g. Ann Oncol. 2015 Jun;26(6):1118-1123. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20. Ann Oncol. 2015. PMID: 25701452 Free article. Clinical Trial.

6

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.

Samardzija C, Luwor RB, Quinn MA, Kannourakis G, Findlay JK, Ahmed N. Samardzija C, et al. Among authors: kannourakis g. BMC Cancer. 2016 Jul 8;16:432. doi: 10.1186/s12885-016-2458-z. BMC Cancer. 2016. PMID: 27390927 Free PMC article.

7

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.

Ahmed N, Greening D, Samardzija C, Escalona RM, Chen M, Findlay JK, Kannourakis G. Ahmed N, et al. Among authors: kannourakis g. Sci Rep. 2016 Jul 29;6:30061. doi: 10.1038/srep30061. Sci Rep. 2016. PMID: 27470985 Free PMC article.

8

Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling.

Samardzija C, Greening DW, Escalona R, Chen M, Bilandzic M, Luwor R, Kannourakis G, Findlay JK, Ahmed N. Samardzija C, et al. Among authors: kannourakis g. Sci Rep. 2017 Apr 13;7:46312. doi: 10.1038/srep46312. Sci Rep. 2017. PMID: 28406185 Free PMC article.

9

The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.

Escalona RM, Chan E, Kannourakis G, Findlay JK, Ahmed N. Escalona RM, et al. Among authors: kannourakis g. Int J Mol Sci. 2018 Feb 2;19(2):450. doi: 10.3390/ijms19020450. Int J Mol Sci. 2018. PMID: 29393911 Free PMC article. Review.

10

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.

Chan E, Luwor R, Burns C, Kannourakis G, Findlay JK, Ahmed N. Chan E, et al. Among authors: kannourakis g. Oncotarget. 2018 Mar 30;9(24):16599-16618. doi: 10.18632/oncotarget.24615. eCollection 2018 Mar 30. Oncotarget. 2018. PMID: 29682172 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page